Individuals with non-migraine headache have a higher risk for tinnitus, sensorineural hearing impairment, and sudden deafness than individuals without chronic headache.
Researchers found evidence for a divergent association between lifetime MDD and the prevalence and severity of symptoms in patients with migraine.
The neuropeptide pituitary adenylate cyclase-activating polypeptide was found to be a migraine trigger in migraines without aura, according to researchers in Denmark.
Acute treatment of migraine with ubrogepant leads to significantly greater rates of pain freedom at two hours than placebo.
In the Boston, Massachusetts area, researchers found data that showed during the summertime humidity precipitated migraine headaches, yet in the wintertime air pollution is associated with a higher incidence of migraine headaches.
Future research should evaluate the difference in mechanisms and effect moderators between more traditional empirically supported behavioral migraine treatments and mindfulness-based cognitive therapy for migraine.
Investigators aimed to evaluate the safety and tolerability of ubrogepant, focusing on hepatic safety, when administered intermittently with high-frequency dosing in healthy participants.
Fremanezumab was found to be effective and well-tolerated in patients with migraine who have failed to respond to prior preventive treatment.
Headache specialist was more likely to use triptans, while non-headache specialists and the headache specialist started prophylaxis at similar rates in eligible participants.
The authors refute a systematic review and meta-analysis of literature on greater occipital nerve block for the treatment of chronic migraine headaches by Shauly and colleagues and published in Plastic and Reconstructive Surgery, citing extensive limitations and claiming the study ultimately raises more questions than answers.